Clonal hematopoiesis in patients with Covid-19 is stable and not linked to an aggravated clinical course

Article Immunology

Monocytes and Macrophages, Targets of Severe Acute Respiratory Syndrome Coronavirus 2: The Clue for Coronavirus Disease 2019 Immunoparalysis

Asma Boumaza et al.

Summary: The study found that monocytes and macrophages from COVID-19 patients can be infected by SARS-CoV-2, leading to secretion of immunoregulatory cytokines and induction of a specific transcriptional program in macrophages. Single-cell analysis in COVID-19 patients revealed lower monocyte counts affecting all subsets, decreased expression of HLA-DR, and increased expression of CD163, regardless of disease severity.

JOURNAL OF INFECTIOUS DISEASES (2021)

Add to Collection

Article Critical Care Medicine

Effect of anakinra versus usual care in adults in hospital with COVID-19 and mild-to-moderate pneumonia (CORIMUNO-ANA-1): a randomised controlled trial

Xavier Mariette et al.

Summary: The study aimed to determine the effectiveness of anakinra in improving outcomes of patients with mild-to-moderate COVID-19 pneumonia, but the results showed that anakinra did not show improvement in patient outcomes. Further studies are needed to assess the efficacy of anakinra in other selected groups of patients with more severe COVID-19.

LANCET RESPIRATORY MEDICINE (2021)

Add to Collection

Article Medicine, Research & Experimental

An immune-based biomarker signature is associated with mortality in COVID-19 patients

Michael S. Abers et al.

Summary: Immune and inflammatory responses are important factors contributing to disease severity in COVID-19. This study identified specific immune-based biomarkers associated with mortality in COVID-19 patients, with some biomarkers consistently higher in those who died compared to those who recovered, suggesting their potential for early prediction of disease outcome.

JCI INSIGHT (2021)

Add to Collection

Article Immunology

Efficacy of canakinumab in mild or severe COVID-19 pneumonia

Falasca Katia et al.

Summary: The study demonstrates that canakinumab therapy could be a valid treatment option for hospitalized adult patients with mild or severe non ICU COVID-19, leading to rapid and long-lasting improvement in oxygenation levels without severe adverse events.

IMMUNITY INFLAMMATION AND DISEASE (2021)

Add to Collection

Article Microbiology